Induction of Maturation and Activation of Human Dendritic Cells: a Mechanism Underlying the Beneficial Effect of Viscum Album As Complimentary Therapy in Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2008 Jun 6

PMID 18533025

Citations 17

Authors

Sri Ramulu Elluru

Jean-Paul Duong van Huyen

Sandrine Delignat

Michel D Kazatchkine

Alain Friboulet

Srini V Kaveri

Jagadeesh Bayry

Affiliations

Soon will be listed here.

Abstract

Background: Viscum album (VA) preparations have been used as a complimentary therapy in cancer. In addition to their cytotoxic properties, they have also been shown to have immunostimulatory properties. In the present study, we examine the hypothesis that the VA preparations induce activation of human DC that facilitates effective tumor regression.

Methods: Four day old monocyte-derived immature DCs were treated with VA Qu Spez at 5, 10 and 15 microg/ml for 48 hrs. The expression of surface molecules was analyzed by flow cytometry. The ability of Qu Spez-educated DC to stimulate T cells was analyzed by allogeneic mixed lymphocyte reaction and activation of Melan-A/MART-1-specific M77-80 CD8+T cells. Cytokines in cell free culture supernatant was analyzed by cytokine bead array assay.

Results: VA Qu Spez stimulated DCs presented with increased expression of antigen presenting molecule HLA-DR and of co-stimulatory molecules CD40, CD80 and CD86. The VA Qu Spez also induced the secretion of inflammatory cytokines IL-6 and IL-8. Further, Qu Spez-educated DC stimulated CD4+T cells in a allogeneic mixed lymphocyte reaction and activated melanoma antigen Melan-A/MART-1-specific M77-80 CD8+T cells as evidenced by increased secretion of TNF-alpha and IFNgamma.

Conclusion: The VA preparations stimulate the maturation and activation of human DCs, which may facilitate anti-tumoral immune responses. These results should assist in understanding the immunostimulatory properties of VA preparations and improving the therapeutic strategies.

Citing Articles

(mistletoe) extract for dogs with cancer?.

Klingemann H Front Vet Sci. 2024; 10:1285354.

PMID: 38234984 PMC: 10793657. DOI: 10.3389/fvets.2023.1285354.

Mistletoe Extracts during the Oncological Perioperative Period: A Systematic Review and Meta-Analysis of Human Randomized Controlled Trials.

Cogo E, Elsayed M, Bhardwaj S, Cooley K, Aycho C, Liang V Curr Oncol. 2023; 30(9):8196-8219.

PMID: 37754510 PMC: 10529072. DOI: 10.3390/curroncol30090595.

The Anti-Inflammatory Activity of .

Nicoletti M Plants (Basel). 2023; 12(7).

PMID: 37050086 PMC: 10096603. DOI: 10.3390/plants12071460.

Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer.

Paller C, Wang L, Fu W, Kumar R, Durham J, Azad N Cancer Res Commun. 2023; 3(2):338-346.

PMID: 36860652 PMC: 9973409. DOI: 10.1158/2767-9764.CRC-23-0002.

Biological activity of mistletoe: in vitro and in vivo studies and mechanisms of action.

Szurpnicka A, Kowalczuk A, Szterk A Arch Pharm Res. 2020; 43(6):593-629.

PMID: 32621089 PMC: 7340679. DOI: 10.1007/s12272-020-01247-w.

References

Augustin M, Bock P, Hanisch J, Karasmann M, Schneider B . Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter,.... Arzneimittelforschung. 2005; 55(1):38-49. DOI: 10.1055/s-0031-1296823. View

Banchereau J, Steinman R . Dendritic cells and the control of immunity. Nature. 1998; 392(6673):245-52. DOI: 10.1038/32588. View

Wolfram R, Budinsky A, Brodowicz T, Kubista M, Kostler W, Kichler-Lakomy C . Defective antigen presentation resulting from impaired expression of costimulatory molecules in breast cancer. Int J Cancer. 2000; 88(2):239-44. View

Stein G, Pfuller U, Schietzel M, Bussing A . Expression of interleukin-4 in apoptotic cells: stimulation of the type-2 cytokine by different toxins in human peripheral blood mononuclear and tumor cells. Cytometry. 2000; 41(4):261-70. DOI: 10.1002/1097-0320(20001201)41:4<261::aid-cyto4>3.0.co;2-s. View

Braun J, Ko H, Schierholz J, Beuth J . Standardized mistletoe extract augments immune response and down-regulates local and metastatic tumor growth in murine models. Anticancer Res. 2003; 22(6C):4187-90. View

Stein G, Bussing A, Schietzel M . Stimulation of the maturation of dendritic cells in vitro by a fermented mistletoe extract. Anticancer Res. 2003; 22(6C):4215-9. View

Rabinovich G, Gabrilovich D, Sotomayor E . Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2006; 25:267-96. PMC: 2895922. DOI: 10.1146/annurev.immunol.25.022106.141609. View

Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu Y . Immunobiology of dendritic cells. Annu Rev Immunol. 2000; 18:767-811. DOI: 10.1146/annurev.immunol.18.1.767. View

Urech K, Schaller G, Jaggy C . Viscotoxins, mistletoe lectins and their isoforms in mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung. 2006; 56(6A):428-34. DOI: 10.1055/s-0031-1296808. View

10.

Bussing A, Schietzel M . Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. Anticancer Res. 1999; 19(1A):23-8. View

11.

Cella M, Sallusto F, Lanzavecchia A . Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol. 1997; 9(1):10-6. DOI: 10.1016/s0952-7915(97)80153-7. View

12.

Natali P, Nicotra M, Bigotti A, Venturo I, Marcenaro L, Giacomini P . Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci U S A. 1989; 86(17):6719-23. PMC: 297917. DOI: 10.1073/pnas.86.17.6719. View

13.

Hostanska K, Hajto T, Spagnoli G, Fischer J, Lentzen H, Herrmann R . A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. Nat Immun. 1995; 14(5-6):295-304. View

14.

Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, Dalerba P . Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev. 2002; 188:97-113. DOI: 10.1034/j.1600-065x.2002.18809.x. View

15.

Wang Z, Cao Y, Albino A, Zeff R, Houghton A, Ferrone S . Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. J Clin Invest. 1993; 91(2):684-92. PMC: 288010. DOI: 10.1172/JCI116249. View

16.

Khwaja T, Dias C, Pentecost S . Recent studies on the anticancer activities of mistletoe (Viscum album) and its alkaloids. Oncology. 1986; 43 Suppl 1:42-50. DOI: 10.1159/000226419. View

17.

Heinzerling L, von Baehr V, Liebenthal C, von Baehr R, Volk H . Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, ex vivo, and in vivo. J Clin Immunol. 2006; 26(4):347-59. DOI: 10.1007/s10875-006-9023-5. View

18.

Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk A . Induction of tolerance by IL-10-treated dendritic cells. J Immunol. 1997; 159(10):4772-80. View

19.

Klopp R, Schmidt W, Werner E, Werner M, Niemer W, Beuth J . Influence of complementary Viscum album (Iscador) administration on microcirculation and immune system of ear, nose and throat carcinoma patients treated with radiation and chemotherapy. Anticancer Res. 2005; 25(1B):601-10. View

20.

Elluru S, Duong van Huyen J, Delignat S, Prost F, Bayry J, Kazatchkine M . Molecular mechanisms underlying the immunomodulatory effects of mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung. 2006; 56(6A):461-6. DOI: 10.1055/s-0031-1296813. View